Camp4 Therapeutics (CAMP) Net Margin (2023 - 2026)

Camp4 Therapeutics has reported Net Margin for 4 years, with the latest figure at 944.13% in Q1 2026.

• Quarterly Net Margin rose 64655.0% year-over-year to 944.13% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1426.56% (up 264218.0% YoY) and the FY2025 annual result came in at 3616.95%, up 1427860.0% from the prior year.
• Net Margin improved to 944.13% in Q1 2026 per CAMP's latest filing, from 2779.02% in the prior quarter.
• Over five years, Net Margin peaked at 944.13% in Q1 2026 and troughed at 3544.0% in Q3 2023.
• A 4-year average of 1950.5% and a median of 1676.99% in 2024 frame the typical range for Net Margin.
• The sharpest annual moves came in 2025 and 2026: Net Margin plunged 110203 bps in 2025, then soared 64655 bps in 2026.
• Over 4 years, Net Margin stood at 3544.0% in 2023, then soared by 53 bps to 1676.99% in 2024, then plunged by 66 bps to 2779.02% in 2025, then soared by 66 bps to 944.13% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 944.13%, 2779.02%, and 1774.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.